Black Diamond Therapeutics (BDTX) will report third-quarter results soon, with a Zacks Consensus Estimate for a loss per share of 22 cents. Earnings estimate for 2025 decreased to 35 cents per share, while loss per share for 2026 widened to 89 cents.

BDTX has a strong track record of beating earnings estimates, with an average surprise of 1,214% in the last four quarters. The company’s earnings beat estimates by 24% in the last reported quarter.

Investors will focus on BDTX’s lead pipeline candidate, silevertinib, during the upcoming earnings report. Silevertinib is a brain-penetrant EGFR MasterKey inhibitor showing promise in treating EGFRm NSCLC and GBM.

BDTX is currently evaluating silevertinib in a phase II study for EGFRm NSCLC, with enrollment completed in frontline patients harboring non-classical EGFR mutations. FDA feedback on a potential registrational path is expected in the first half of 2026.

Year to date, BDTX shares have surged 78.5%, outperforming the industry and sector. The stock is also undervalued based on the price/book ratio, trading lower than its mean and industry average.

Despite positive developments, BDTX has only one pipeline candidate, making any setback in silevertinib’s development risky for investors. Prospective investors should wait for further progress, while current investors may consider staying invested for potential positive data readouts.

Stay updated on BDTX’s progress with silevertinib, as any positive news could boost the stock price. Check out the latest recommendations from Zacks Investment Research for insights on investing strategies.

Read more at Nasdaq: Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?